TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle
Pompe disease (PD) is a lysosomal disorder caused by acid α-glucosidase (GAA) deficiency. Progressive muscular weakness is the major symptom of PD, and enzyme replacement therapy can improve the clinical outcome. However, to achieve a better clinical outcome, alternative therapeutic strategies are b...
Main Authors: | Yohei Sato, Hiroshi Kobayashi, Takashi Higuchi, Yohta Shimada, Hiroyuki Ida, Toya Ohashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300268 |
Similar Items
-
Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient
by: Yohei Sato, et al.
Published: (2015-01-01) -
GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
by: Erik van der Wal, et al.
Published: (2017-06-01) -
Targeted Integration of Inducible Caspase-9 in Human iPSCs Allows Efficient <i>in vitro</i> Clearance of iPSCs and iPSC-Macrophages
by: Alexandra Lipus, et al.
Published: (2020-04-01) -
The CIRM iPSC repository
by: Stephen S. Lin, et al.
Published: (2020-04-01) -
CiRA iPSC seed stocks (CiRA's iPSC Stock Project)
by: Tadaaki Hanatani, et al.
Published: (2021-01-01)